SUNNYVALE, CA--(Marketwire - August 12, 2009) - Arrayit Corporation (OTCBB: ARYC), a proprietary life science technology leader, announces the incorporation of Arrayit Diagnostics, Inc., a majority owned Nevada Corporation, to be headquartered in Houston, Texas. The company is currently developing several diagnostic tests for cancer, neurodegenerative disease, and other disease states. Arrayit Diagnostics will promote the commercialization of these tests using Arrayit's microarray platform. By conclusively identifying the genomic and proteomic biomarkers for specific diseases, these tests will allow early stage diagnosis leading to life saving and cost saving treatment protocols.
Arrayit Diagnostics is being put in position to launch one of the most intensive marketing campaigns in Arrayit's twelve year history. Supported by a massive network of 41 international life science and diagnostics distributors located in 38 countries, Arrayit will use this opportunity to expand its worldwide customer base of 10,000 research labs to become a significant global diagnostics company.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 10,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this
release that constitute forward-looking statements are based on currently
available information, involve certain risks and uncertainties and the
Company assumes no responsibility to update any such forward-looking
statement. The following factors, among others, may cause actual results to
differ materially from the results suggested in the forward-looking
statements. Risks that may result from changes in the Company's business
operations; our ability to keep pace with technological advances;
significant competition in the biomedical business; our relationships with
key suppliers and customers; quality and consumer acceptance of newly
introduced products; market volatility; non-availability of product; excess
inventory; price and product competition; new product introductions, the
outcome of our legal disputes; the possibility that the review of our prior
filings by the SEC may result in changes to our financial statements; and
the possibility that stockholders or regulatory authorities may initiate
proceedings against Arrayit and/or our officers and directors as a result
of any restatements. Risk factors associated with our business, including
some of the facts set forth herein, are detailed in the Company's Form
10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the
fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal
third quarter ended September 30, 2008.
Investor Contact:
Arrayit Corporation
Tel: 408-744-1331
investorinfo@arrayit.com
www.arrayit.com
Media Contact:
Rod Mitchell
Tel: 281-350-5506
mediarod@aol.com